GlassScriptPhysician profile
Jiten P Kothadia
NPI 1245636596
$5,660.91
in general payments reported to CMS, 2019-2025
14 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.40 · 2021: $119 · 2022: $4,466 · 2023: $244 · 2024: $405 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.77 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $4,424.38 | 2022 | |
| Janssen Biotech, INC. | $286.29 | 2023-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.61 | 2021-2023 | Xifaxan |
| Madrigal Pharmaceuticals | $175.29 | 2024-2025 | Resmetirom, Rezdiffra |
| Novo Nordisk INC | $170.39 | 2024-2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $112.73 | 2023 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $111.89 | 2025 | Entyvio |
| Gilead Sciences, INC. | $68.02 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $41.13 | 2022 | |
| Lilly USA, LLC | $22.91 | 2025 | Omvoh |
| Celltrion USA INC. | $21.15 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $19.12 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiten Kothadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.